Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELDN Eledon Pharmaceuticals, Inc.

Trading 05-07 15:33:41 EDT

3.87

+0.07

+1.84%

High3.93	Low3.67	Vol1.05M
Open3.86	D1 Closing3.80	Amplitude6.71%
Mkt Cap298.72M	Tradable Cap265.42M	Total Shares77.19M
T/O4.00M	T/O Rate1.53%	Tradable Shares68.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELDN","market":"US","secType":"STK","nameCN":"Eledon Pharmaceuticals, Inc.","latestPrice":3.87,"timestamp":1778182420775,"preClose":3.8,"halted":0,"volume":1049165,"delay":0,"changeRate":0.018421052631579022,"floatShares":68583200,"shares":77187800,"eps":-0.556639,"marketStatus":"Trading","change":0.07,"latestTime":"05-07 15:33:41 EDT","open":3.86,"high":3.925,"low":3.67,"amount":3996061.75033,"amplitude":0.067105,"askPrice":3.87,"askSize":427,"bidPrice":3.86,"bidSize":1136,"shortable":3,"etf":0,"ttmEps":-0.556639,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778184000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.8,"preHourTrading":{"tag":"盘前","latestPrice":3.929,"preClose":3.8,"latestTime":"09:22 EDT","volume":5375,"amount":21016.9836875,"timestamp":1778160160117,"change":0.129,"changeRate":0.033947,"amplitude":0.039474},"postHourTrading":{"tag":"盘后","latestPrice":3.8165,"preClose":3.8,"latestTime":"19:55 EDT","volume":7999,"amount":30212.4706,"timestamp":1778111730232,"change":0.0165,"changeRate":0.004342,"amplitude":0.036842},"volumeRatio":0.903706,"impliedVol":1.8823,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/ELDN","defaultTab":"news","newsList":[{"id":"2632647049","title":"Eledon Pharmaceuticals Files $500 Million Mixed Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647049","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647049?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:32","pubTimestamp":1777667534,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals  filed a registration statement late Friday for the potential sale of up to $500 million of securities from time to time.The filing covers common and preferred stock, debt securities, warrants and units.Net proceeds will be used for general corporate purposes, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647934","title":"Eledon Pharmaceuticals files $500M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647934?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:15","pubTimestamp":1777666519,"startTime":"0","endTime":"0","summary":"16:10 EDT Eledon Pharmaceuticals (ELDN) files $500M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-files-500m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-files-500m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634773","title":"Newcelx Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634773","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634773?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:15","pubTimestamp":1777551300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA4KWLWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631348286","title":"EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2631348286","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631348286?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:01","pubTimestamp":1777550469,"startTime":"0","endTime":"0","summary":"NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/04/52166830/exclusive-newcelx-eyes-accelerated-2026-execution-for-diabetes-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629082759","title":"Eledon Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629082759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629082759?lang=en_us&edition=fundamental","pubTime":"2026-04-21 18:01","pubTimestamp":1776765710,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals scheduled annual stockholders meeting for June 18, 2026 in Irvine, California.Shareholders to vote on election of Class III directors David-Alexandre C. Gros, Jan Hillson, James Robinson to terms ending at 2029 annual meeting.Ballot includes charter amendment to raise authorized common stock to 450,000,000 shares from 300,000,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL998MB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628474697","title":"NewcelX publishes updated corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628474697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628474697?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:37","pubTimestamp":1776685072,"startTime":"0","endTime":"0","summary":"NewcelX published updated corporate presentation highlighting Type 1 Diabetes flagship program NCEL-101.Presentation includes strategic collaboration with Eledon integrating NewcelX stem-cell-derived islet replacement platform with Eledon anti-CD40L monoclonal antibody tegoprubart.Update frames combined approach as strategy to support durable graft survival for Type 1 Diabetes.Management plans to present updated materials at Swiss Biotech Conference.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbTDVY4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","ELDN","NCEL","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621066972","title":"Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066972","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621066972?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347453,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/is-eledon-pharmaceuticals-nasdaqeldn-in-a-good-position-to-d-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/is-eledon-pharmaceuticals-nasdaqeldn-in-a-good-position-to-d-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","ELDN","TSYW.SI","USJW.SI","GPIQ","PSQ","QYLG","QID","QLD","QQQE","MNQmain",".IXIC","BK4139","QQQJ","NVIW.SI","JEPQ","NQmain","QQQY","USAW.SI","TQQQ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620723592","title":"Eledon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620723592","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620723592?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:25","pubTimestamp":1773959153,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryEledon Pharmaceuticals Inc ELDN.OQ reported a quarterly adjusted loss of 10 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N40731L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620227426","title":"Corrected-Eledon Pharmaceuticals: FY (Not 'Q4') EPS $-0.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2620227426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620227426?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:08","pubTimestamp":1773958105,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N407314:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620271286","title":"Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271286","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271286?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:19","pubTimestamp":1773955160,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals 2025 net loss widens on higher R&D costsOverviewUS biotech firm's 2025 net loss widenes, R&D expenses increased for clinical programsCompany secured FDA Orphan Drug designation ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL1N4071JZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620711262","title":"Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620711262","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620711262?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:13","pubTimestamp":1773954822,"startTime":"0","endTime":"0","summary":"Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of $(0.64) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51369919/eledon-pharma-q4-eps-0-10-beats-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620160271","title":"Eledon Pharmaceuticals FY Operating Expenses USD 83.251 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620160271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620160271?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:10","pubTimestamp":1773954639,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX980064:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620271146","title":"Press Release: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271146","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271146?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:10","pubTimestamp":1773954600,"startTime":"0","endTime":"0","summary":"Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study. Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart. Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation. IRVINE, Calif., March 19, 2026  -- Eledon Pharmaceuticals, Inc.   today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights.the U.S. Food and Drug Administration  for the prevention of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620271962","title":"Eledon Pharmaceuticals: Q4 EPS $-0.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271962?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:05","pubTimestamp":1773954359,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4071C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620927161","title":"Eledon FY 2025 net loss was USD 45.6 million as R&D expenses rose 27.5% to USD 66.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620927161","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620927161?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:02","pubTimestamp":1773954172,"startTime":"0","endTime":"0","summary":"Eledon filed a Form 8-K reporting fourth-quarter and full-year 2025 operating and financial results, including R&D expense of USD 66.3 million.General and administrative expense was USD 17.0 million, while net loss was USD 45.6 million, or USD 0.52 per basic share.R&D expense rose 27.5%, driven by expanded tegoprubart clinical trial activity, manufacturing scale-up, and increased personnel.G&A expense fell 8.6%, reflecting lower stock-based compensation expense, partially offset by higher professional services and personnel-related costs.David-Alexandre Gros said the company expects regulatory engagement to support advancement into Phase 3 development in kidney transplantation and plans to initiate additional investigator-led trials in islet and liver transplantation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6rv0cV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620757982","title":"Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2620757982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620757982?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:20","pubTimestamp":1773948017,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Eledon Pharmaceuticals (ELDN) is normal with calls leading puts 724:1. Implied volatility suggests the market is ant...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-options-imply-11-7-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-options-imply-11-7-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620311922","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620311922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620311922?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:00","pubTimestamp":1773828000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Accenture Plc A                                  2Q      2.85   6:39 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLY","GUTS","CLLS","ABVX","DRIO","GANX","GEMI","GIS","FUFU","CCL","ARCO","ABSI","ARX","CURV","CNM","BRAG","AEBI","MXCT","ETON","AVAH","CRIS","ECOR","ALVO","DRI","FBRX","BIOA","BRZE","EQPT","FIVE","AIR","CUK","BABA","BGSI","FDX","BZ","CDNL","DLO","ELDN","ACN","CELC","CNXC","GRWG","HNRG","CAL","DERM","EVTL","CING","BZAI","AVR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619661134","title":"Sernova Biotherapeutics publishes MD&A for the three months ended Jan. 31, 2026 and 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2619661134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619661134?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:36","pubTimestamp":1773668208,"startTime":"0","endTime":"0","summary":"Sernova published its MD&A report, highlighting interim Phase 1/2 type 1 diabetes data from 12 patients showing 8 patients achieving insulin independence, with the first treated patient sustaining insulin independence for more than 4 years. The company said Cohort B uses an optimized 10-channel Cell Pouch with 56% greater islet capacity than the Cohort A device, and it expects confirmatory Cohort C to initiate in H2 2026 pending additional funding. Sernova reported it received FDA authorization for an IND to evaluate Cell Pouch with auto-transplanted thyroid cells in patients undergoing total thyroidectomy for nodular thyroid disease. The company said it plans to use Eledon’s tegoprubart in Cohort C in place of tacrolimus, and noted Eledon reported all six subjects in a separate portal-vein islet transplant trial achieved insulin independence after one or two transplants. Sernova reported a working capital deficit of CAD 24.76 million as of January 31, 2026, and said it expects additio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL8BwZ52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619513450","title":"Eledon announces updated data from islet transplant trial of tegoprubart","url":"https://stock-news.laohu8.com/highlight/detail?id=2619513450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619513450?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660646,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals (ELDN) announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eledon-announces-updated-data-from-islet-transplant-trial-of-tegoprubart-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eledon-announces-updated-data-from-islet-transplant-trial-of-tegoprubart-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619578964","title":"Eledon Pharmaceuticals Inc  expected to post a loss of 20 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619578964","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619578964?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:12","pubTimestamp":1773659544,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc  expected to post a loss of20cents a share - Earnings Preview Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected to  show no change in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N4040TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eledon.com","stockEarnings":[{"period":"1week","weight":0.1377},{"period":"1month","weight":0.2298},{"period":"3month","weight":0.9289},{"period":"6month","weight":0.8447},{"period":"1year","weight":0.324},{"period":"ytd","weight":1.5166}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.166113},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000872},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.044379},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009056},{"month":5,"riseRate":0.583333,"avgChangeRate":0.747819},{"month":6,"riseRate":0.181818,"avgChangeRate":-0.182936},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.081289},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.035259},{"month":9,"riseRate":0.272727,"avgChangeRate":0.085532},{"month":10,"riseRate":0.5,"avgChangeRate":2.263696},{"month":11,"riseRate":0.5,"avgChangeRate":-0.069266},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.094259}],"exchange":"NASDAQ","name":"Eledon Pharmaceuticals, Inc.","nameEN":"Eledon Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eledon Pharmaceuticals, Inc.,ELDN,Eledon Pharmaceuticals, Inc.股票,Eledon Pharmaceuticals, Inc.股票老虎,Eledon Pharmaceuticals, Inc.股票老虎国际,Eledon Pharmaceuticals, Inc.行情,Eledon Pharmaceuticals, Inc.股票行情,Eledon Pharmaceuticals, Inc.股价,Eledon Pharmaceuticals, Inc.股市,Eledon Pharmaceuticals, Inc.股票价格,Eledon Pharmaceuticals, Inc.股票交易,Eledon Pharmaceuticals, Inc.股票购买,Eledon Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction